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Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent
suppression of Erk1/2 activation and Egr-1–mediated transcriptional events
*Jai-Hyun Kim,1 *Dong Soon Choi,1 Ok-Hee Lee,1 Seung-Hyun Oh,1 Scott M. Lippman,1 and Ho-Young Lee1,2
1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX; and 2Research Institute of
Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, Korea
Most antiangiogenic therapies currently
being evaluated in clinical trials target
the vascular endothelial growth factor
pathway; however, the tumor vascula-
ture can acquire resistance to vascular
endothelial growth factor-targeted therapy
by shifting to other angiogenesis mecha-
nisms. Insulin-like growth factor binding
protein-3 (IGFBP-3) has been reported to
suppress tumor growth and angiogen-
esis by both IGF-dependent and IGF-
independent mechanisms; however, un-
derstanding of its IGF-independent
mechanisms is limited. We observed that
IGFBP-3 blocked tumor angiogenesis and
growth in non–small cell lung cancer and
head and neck squamous cell carcinoma.
Conditioned media from an IGFBP-3–
treated non–small cell lung cancer cell
line displayed a significantly decreased
capacity to induce HUVEC proliferation
and aortic sprouting. In cancer cells,
IGFBP-3 directly interacted with Erk1/2,
leading to inactivation of Erk1/2 and Elk-1,
and suppressed transcription of early
growth response protein 1 and its target
genes, basic fibroblast growth factor and
platelet-derived growth factor. These data
suggest that IGF-independent Erk1/2 inac-
tivation and decreased IGFBP-3–induced
Egr-1 expression block the autocrine and
paracrine loops of angiogenic factors in
vascular endothelial and cancer cells. To-
gether, these findings provide a molecular
framework of IGFBP-3’s IGF-independent
antiangiogenic antitumor activities. Fu-
ture studies are needed for develop-
ment of IGFBP-3 as a new line of anti-
angiogengic cancer drug. (Blood. 2011;
118(9):2622-2631)
Introduction
Angiogenesis, the formation of new capillaries from existing
blood vessels, is essential to carcinogenic processes, including
solid tumor formation, growth, invasion, and metastasis.1 Most
tumors can stimulate angiogenesis by switching on the produc-
tion of numerous cytokines and growth factors, including
fibroblast growth factors (FGFs), vascular endothelial growth
factors (VEGFs), and platelet-derived growth factors (PDGFs).2
Several antiangiogenic agents are in various phases of clinical
trials for human cancer; however, most of these agents target the
VEGF signaling pathway.3 Therefore, other potential therapeu-
tic agents that block non-VEGF angiogenic pathways need to
be evaluated.
Insulin-like growth factor-binding protein-3 (IGFBP-3), a mem-
ber of a family of 6 IGFBPs, has demonstrated antiproliferative,
proapoptotic, antiangiogenic, and antimetastatic activity in a vari-
ety of cancer cells.4-8 It may also have IGF-independent antitumor
activities through cell-surface or intracellular protein interaction,
its nuclear translocation, or its transcriptional regulation.7,9-12
However, the mechanisms that mediate IGFBP-3’s IGF-indepen-
dent antitumor activity have not been clearly defined.
The 82-kDa phosphoprotein transcription factor early growth
response protein 1 (Egr-1), an immediate early gene product, has
been implicated in multiple cellular processes, including cell
growth, apoptosis, wound healing, and angiogenesis. Mitogenic
stimuli, including serum, PDGF, peptide growth factors, and
B-Raf, and nonmitogenic stresses, including -irradiation and
hypoxia, activate Egr-1 expression through serum response ele-
ments (SREs) in the Egr-1 promoter, where serum response factor
(SRF) and ternary complex factors form transcriptionally active
ternary complexes.13 Once activated, Egr-1 binds to GC-rich,
cis-acting promoter elements and controls the expression of
multiple genes that encode growth factors, cytokines, adhesion
molecules, and proteases, including IGF-1, IGF-2, TGF-1, fi-
bronectin, urokinase-type plasminogen activator, VEGF-1R, VEGF,
PDGF-A and -B, and basic FGF (bFGF), which are believed to
have important functions in cancer cell survival, apoptosis, angio-
genesis, invasion, and metastasis.14,15 The association between
Egr-1 and tumor angiogenesis has been observed in various tumor
types.16-18 A DNA-based enzyme and a siRNA that target Egr-1
suppress bFGF expression and tumor angiogenesis and growth in
various cancer cell types.18-21
In this study, we determined the mechanisms by which IGFBP-3
exerts its IGF-independent antiangiogenic antitumor activity. Our
findings reveal that IGFBP-3’s engagement of Erk1/2 inactivates
Erk1/2 and Elk1 in an IGF-independent manner, resulting in
inhibited binding of Elk1 to SRE sites in the Egr-1 upstream
promoter and reduced transcription of Egr-1 and its target genes,
including PDGF and bFGF. Egr-1, bFGF, and PDGF proteins were
highly down-regulated in our non–small cell lung cancer (NSCLC)
mouse models; we also observed angiogenesis suppression. These
data suggest that increase in IGFBP-3 level could lead to inhibition
of tumor angiogenesis.
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Methods
Cell culture, animals, and other reagents
H460, H1299, A549 (NSCLC cell lines), UMSCC38 (head and neck squamous
cell carcinoma [HNSCC] cell lines), and HUVEC (Cambrex Bio Science) cell
lines were cultured as previously described.8 NSCLC cell lines (H1299, A549,
and H460) and HUVEC were cultured in RPMI 1640 with 10% FBS and in
EGM (Lonza Walkersville Inc), respectively, in a humidified environment with
5% CO2. Six-week-old female athymic nude mice (10 mice for each group)
and chick eggs (Harlan-Sprague-Dawley and Charles River laboratories)
were maintained in a defined pathogen-free environment. All animal
procedures were performed in accordance with a protocol approved by the
M. D. Anderson Institutional Animal Care and Usage Committee.
Tumor xenograft model and immunohistochemical analysis
Ad-BP-3’s antiangiogenic effects on established H1299 subcutaneous or
UMSCC38 HNSCC orthotopic tumor models were determined as described
elsewhere.8,11,22 In brief, after the H1299 xenograft tumor volume reached
 75 mm3, mice (n  5) were given single intratumoral injections (1  1010
particles) of IGFBP-3–expressing (Ad-BP-3) or empty viruses (Ad-EV).
Tumors embedded in paraffin were subjected to immunohistochemical
staining by the use of an ABC staining kit (Vector Laboratories) with
anti-bFGF (1:400 dilution), anti-PDGF (1:400 dilution), and anti–Egr-1
(1:400 dilution) antibodies. For CD31 staining, frozen tumor tissue sections
were stained with anti-CD31 antibody (1:100 dilution).
Matrigel plug assay
The in vivo mouse Matrigel plug assay was performed with A549 NSCLC
cells infected with Ad-BP-3 (50 pfu/cell) or Ad-EV (50 pfu/cell). Each
treatment group included 10 mice. The number of blood vessels per field
was analyzed by microscopy at 10magnification.
Cell proliferation, migration, invasion, and tube-formation assay
The in vitro migration, invasion, and tube-formation assays were performed
as described elsewhere.8,23,24 In brief, in the coculture assay with H460
cells, HUVECs (4  104) were seeded onto the cell culture inserts (1-m
pore size; Becton Dickinson) and H460 cells (2  105) transfected with
pBP-3, pBP-3-ggg, or pEgr1 were transferred to the bottom of a 12-well
plate. Three days later, HUVEC proliferation was assessed by use of the
MTT assay. To determine IGFBP-3’s effects on NSCLC cells’ angiogenesis-
stimulating effects, we infected H1299, H460, and A549 cells with Ad-BP-3
(50 pfu/cell) or Ad-EV or treated them with rBP-3 or control vehicle, as
previously described.25 Conditioned media (CM) were collected from
NSCLC cells and added to HUVECs for cell proliferation or tube formation
or to check aortas for endothelial cell sprouting, as previously described.8,24
HUVEC tube formation was scored after 8 hours, and cell proliferation was
analyzed by the MTT assay after 3 days, as previously described.26 Each
condition was tested in 6 wells. The details are described in supplemental
Methods (available on the Blood Web site; see the Supplemental Materials
link at the top of the online article).
Transcription analysis
Quantitative RT-PCR was performed as described elsewhere.27 The primer
sequences used are described in supplemental Methods. To avoid amplification of
genomic DNA, each gene primer was chosen from different exons. To analyze
the bFGF promoter, we amplified the 5-flanking region (590 to 	26) of the
human bFGF gene (GenBank accession number: NM_002006) from human
genomic DNA (Sigma-Aldrich) and cloned into the SmaI site of the luciferase
reporter vector pGL3-Basic (Promega). The detailed methods used to construct
the mutant Egr-1 promoter vectors, transfect plasmids and siRNAs, and per-
form the luciferase reporter assay are described in supplemental Methods.
ChIP
A ChIP assay was performed with H460 cells infected with Ad-BP-3 or
Ad-EV or treated with rBP-3 or control vehicle. Extracts from equal
numbers of cells were immunoprecipitated with antibodies against Elk-1,
SRF, IGFBP-3, or preimmune serum as a negative control. PCR was
performed with the use of primers encompassing the SRE elements, as
depicted in Figure 5A, and an exon 1 primer was used as a negative control.
All PCR primers and conditions are described in the supplemental Methods.
An aliquot of the whole-cell protein-DNA complex (2% of the immunopre-
cipitated volume) was subjected to PCR analysis to confirm the protein-
bound DNA sequence.
Immunoprecipitation, in vitro pull, and Western blot analyses
H1299 cells were transfected with 5 g of control (EV) or pCMV6-IGFBP-
3-Flag (pBP-Flag). After they were starved of serum, the cells were
stimulated with 10% FBS for 0 and 20 minutes. Whole-cell lysates were
prepared, and Western blotting was performed as described elsewhere.28
For immunoprecipitation, total cell lysates were precleared with the
appropriate protein-G or protein-A beads and then incubated with goat
antibody (1 g) against Erk1/2 or rabbit antibody against p38
 and
protein-G or protein-A beads. IGFBP-3-Flag binding was detected with a
mouse anti-Flag antibody. For the in vitro pulldown assay, rBP-3 (1 g)
conjugated to NTA-agarose beads (50 L, 50% slurry) was incubated with
H1299 cell lysate (150, 300, and 450 g) and then washed with PBS and
10mM imidazole. The beads were then boiled in 2 sample buffer for
10 minutes and used for the Western blot analysis. For the negative control,
blank BSA-coated NTA beads were incubated with 450 g of cell lysate.
Immunofluorescence staining
H1299 cells were seeded on cover slips (Deckgla¨ser; Menzel-Gla¨ser)
coated with rat tail collagen type I (100 g/mL; BD Biosciences). After
being incubated overnight, the cells were serum-starved for 3 hours and
treated with rhIGFBP-3 at 10 g/mL in a serum-free medium (RPMI
1640) and fixed at 0, 10, 30, and 60 minutes in 4% paraformaldehyde in
PBS for 3 minutes. After being thoroughly washed with PBS, the cells
were treated with methanol on ice and washed with PBS. After blocking
with 5% BSA, primary rabbit anti-IGFBP-3 (Santa Cruz Biotechnology)
and mouse anti-Erk1/2 (Cell Signaling Technology) antibodies were
added to the cells overnight at 4°C. After being washed in PBS, the
cells were stained with donkey anti–rabbit antibodies conjugated with
Alexa Fluor 568 and donkey anti–mouse antibodies conjugated with Alexa
Fluor 488. During the washing steps, the cells were stained with Hoechst
33342. The cover slips were mounted and imaged with the use of an
Olympus IX71 FV 500 laser confocal microscope with Fluoview Version
5.0 software. All images were obtained with a 60 objective lens with
2 optical zoom. The colocalization analysis was performed by use of the
colocalization finder function of ImageJ software (NIH).
Statistical analysis
Data are given as the mean  SD. To determine the statistical significance
between groups, we used paired Student t tests and 95% confidence
intervals. In all statistical analyses, 2-sided P values .05 were considered
statistically significant.
Results
IGFBP-3 inhibits NSCLC and HNSCC tumor growth and
angiogenesis
We previously demonstrated that IGFBP-3 overexpression inhibits
the growth of H1299 NSCLC xenografts in nude mice.11 To
determine whether IGFBP-3’s antiangiogenic activity contributes
to its antitumor activities, we performed a series of experiments by
using adenoviral (Ad-BP-3) and recombinant (rBP-3) IGFBP-3.
We first determined Ad-BP-3’s effect on tumor growth and
angiogenesis in 1299 NSCLC xenograft tumors established in
athymic nude mice. Ad-BP-3 induced significant decreases in
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H1299 NSCLC xenograft tumor growth (Figure 1A). Anti-CD31
staining of the tumor tissues injected with Ad-BP-3 revealed
significantly decreased tumor vascularization compared with those
injected with control viruses (AD-EV; Figure 1A right). The
Matrigel plugs that contained Ad-BP-3–infected A549 cells had
significantly fewer blood vessels than did those containing Ad-EV
cells (P  .01; Figure 1B). These findings suggest that IGFBP-3
has antiangiogenic and antitumor activity in NSCLC.
Tumor angiogenesis is partly mediated by tumor-secreted
angiogenic growth factors that interact with their receptors ex-
pressed on endothelial cells.29 To determine whether IGFBP-3
suppresses the secretion of angiogenic factors from NSCLC, we
collected CM from Ad-EV– or Ad-BP-3–infected H1299 cells after
incubating them in a serum-free medium for 1 day. As shown in
Figure 1C, HUVECs that had been treated with CM from untreated
(Con) or Ad-EV–infected cells, but not from Ad-BP-3–infected
cells, demonstrated significantly greater proliferation than did
those treated with endothelial cell basal medium only. The ex vivo
chick aortic ring arch assay showed similar results; the CM from
untreated or Ad-EV–infected cells, but not the CM from Ad-BP-3–
infected cells, significantly stimulated the formation of endothelial
cell sprouts (Figure 1D).
Because protein expression induced by adenoviruses can be
much greater than that seen under real-life conditions, we further
determined the effects of exogenously added recombinant IGFBP-3
(rBP-3), which has a cytosolic half-life of 3 hours.28 We performed
a Western blot analysis to confirm that no residual rBP-3 was
present in the CM (data not shown). HUVECs that had been treated
with the CM from BP-3–pretreated cancer cells also showed
significantly reduced proliferation (Figure 1E) and tube formation
(Figure 1F) compared with those treated with CM from untreated
NSCLC cells. These findings suggest that IGFBP-3 has antiangio-
genic and antitumor activity in NSCLC, at least partly because of
its effects on NSCLC cells’ secretion of angiogenic factors.
IGFBP-3 induces down-regulation of the bFGF-Egr-1
transcription loop
We assessed the angiogenic factors that are regulated by IGFBP-3.
Consistent with previous findings in which IGFBP-3 was found to
mediate the antiangiogenic action of the farnesyl transferase
inhibitor SCH66336, which suppresses VEGF expression in NSCLC
and HNSCC cells,8,30 Ad-BP-3 reduced VEGF expression in
H1299 and A549 NSCLC cells (unpublished data). We determined
IGFBP-3’s effects on bFGF expression. Ad-BP-3 led to decreased
bFGF expression in H1299, A549, and H460 NSCLC cells and
UMSCC38 HNSCC cells (Figure 2A) over the range of doses used
in the cell-based experiments described in Figure 1. IGFBP-3’s
Figure 2. IGFBP-3 down-regulates bFGF transcription. (A) Western blot analysis
of IGFBP-3 and bFGF expression in NSCLC and HNSCC cells 2 days after infection
with Ad-EV or Ad-BP-3. (B) Reduced bFGF levels in the CM from rBP-3–treated
UMSCC38 cells. N.S. indicates nonspecific bands. (C) Semiquantitative RT-PCR
analysis of bFGF expression in H460 cells infected with Ad-EV or Ad-BP-3 (left) or
transfected with scrambled (Con) or IGFBP-3 (BP-3) siRNA (right). (D) Luciferase
assay to determine the effect of IGFBP-3 on bFGF promoter activity in H460 cells
transiently transfected with bFGF-Luc in association with Ad-BP-3 or Ad-EV infection
at the indicated doses (left), rBP-3 treatment (middle), or scrambled (Con) or
IGFBP-3 (BP-3) siRNA cotransfection (right). The results represent the means (bars,
SDs) of triplicate results. *P  .05; **P  .01; ***P  .001.
Figure 1. IGFBP-3 suppresses tumor growth and angiogenesis in NSCLC
xenografts and vascular endothelial cells. (A) H1299 xenograft tumor growth (left)
10 days after injection with IGFBP-3–expressing adenoviruses (Ad-BP-3) or empty
viruses (Ad-EV). Tumor growth is expressed as the mean  SEM. An immunohisto-
chemical analysis of CD31 (right) was performed in xenograft tissues, and the
number of CD31-immunoreactive vessels per high-power field was counted. The
results represent the mean calculated from 5 mice (bars, SDs). *P  .05 compared
with the control group. Representative CD31 immunostaining in H1299 xenograft
tissues is included. (B) Matrigel plug assay with A549 cells. Gross observed results of
blood vessels are expressed as the mean of 5 tumors SEM, **P  .01. (C-D) Effect
of CM from indicated NSCLC cell lines that had been infected with Ad-EV or Ad-BP-3
(C-D) or treated with rBP-3 (E-F) on HUVEC proliferation (C,E), chick aortic sprouting
(D), and HUVEC tube formation (F). The results represent the means (bars, SDs) of
5 identical wells. *P  .05; **P  .01; ***P  .001.
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ability to reduce bFGF protein expression was further confirmed by
a Western blot analysis of rBP-3–treated H1299 cells (supplemen-
tal Figure 1). A CM analysis from UMSCC38 cells revealed that
rBP-3 reduced bFGF secretion (Figure 2B). Ad-BP-3 negatively
regulated bFGF transcription in H460 cells (Figure 2C). Con-
versely, IGFBP-3 knockdown by siRNA led to increased bFGF
mRNA levels. We then determined IGFBP-3’s effects on bFGF
promoter activity by transiently transfecting H460 cells with a
pGL3-basic luciferase reporter construct that contained the 5-
flanking promoter region of human bFGF (589 to 	26). bFGF
promoter activity was significantly reduced after Ad-BP-3 infection
or rBP-3 treatment but increased after IGFBP-3 siRNA transfection
(Figure 2D). Together, these data demonstrate the inhibitory effects
of IGFBP-3 on bFGF transcription.
We next determined which transcription factors are involved in
IGFBP-3–regulated bFGF promoter activity. The Egr-1 and Sp-1
transcription factors have long been recognized as MAPK-
dependent activators of bFGF transcription.13,31,32 Therefore, we
determined IGFBP-3’s effects on Egr-1 and Sp-1 expression.
Infection of H460 cells with Ad-BP-3 dramatically reduced Egr-1
expression at the protein and mRNA levels, with no detectable
changes in Sp-1 expression of (Figure 3A). RT-PCR (supplemental
Figure 2A) and Northern blot (supplemental Figure 2B) analyses
further confirmed rBP-3’s and Ad-BP-3’s ability to reduce bFGF
and Egr-1 mRNA levels. A band shift analysis revealed a reduction
in nuclear complexes bound to the Egr-1 gene promoter in
Ad-BP-3–infected H460 cells compared with in Ad-EV–infected
cells (supplemental Figure 2C). These findings suggest that IGFBP-3
inhibits Egr-1 expression, leading to reduced bFGF promoter
activity and attenuated bFGF expression.
To determine Egr-1’s effect on IGFBP-3–mediated antiangio-
genic activity in NSCLC cells, we transiently cotransfected H460
cells with the bFGF luciferase reporter construct and an Egr-1
expression vector, an IGFBP-3 expression vector (pBP-3), or both.
As shown in Figure 3B, Egr-1 expression led to a dose-dependent
increase in bFGF promoter activity (left) and attenuated IGFBP-3’s
inhibitory effects on promoter activity (right). These results
indicate that Egr-1 plays a specific role in IGFBP-3–mediated
suppression of bFGF transcription. IGFBP-3 also inhibited the
expression of PDGF, another Egr-1–regulated angiogenic factor, as
shown by the results of an RT-PCR analysis of PDGF-a and -b
mRNA levels in H460 cells (Figure 3C) and a Western blot analysis
of PDGF protein expression in H1299 and A549 cells (Figure 3D)
that had been infected with Ad-BP-3 or treated with rBP-3. An
immunohistochemical analysis of H1299 xenografts injected with
Ad-BP-3 (Figure 1A) also demonstrated reduced Egr-1, bFGF, and
PDGF staining (Figure 3E). Collectively, these results demonstrate
that IGFBP-3–mediated Egr-1 suppression results in decreased
bFGF and PDGF expression.
IGFBP-3 suppresses Egr-1 promoter activity in an
IGF-independent manner
The conventional function of IGFBP-3 is to regulate cell growth and
promote apoptosis by sequestering free IGFs. However, studies have
shown that IGFBP-3 also has IGF-independent antitumor activity.4,33 To
determine whether Egr-1 transcription regulation by IGFBP-3 is IGF
dependent, we cotransfected H460 cells with a human Egr-1 reporter
construct and expression vectors carrying K-ras (V12) or H-ras (V12),
along with pBP-3 or an empty vector control.
Transfection with pBP-3 resulted in substantial loss of the Egr-1
promoter activity that had been stimulated by K-ras (V12) and
H-ras (V12; Figure 4A). Egr-1 transcription is known to be
activated by environmental stresses, such as hypoxia and radia-
tion.34,35 Egr-1 promoter activity, stimulated by -radiation (8 Gy)
or incubation in 1% O2, was significantly suppressed by pBP-3
(Figure 4A right). We also found that pBP-3-ggg, a mutant
IGFBP-3 with a substitution of 3 glycine residues (Gly56Gly80Gly81)
that are critical for the IGF binding domain,33 inhibited the Egr-1
promoter activity stimulated by IGF-1, FBS, or constitutively
Figure 3. IGFBP-3 down-regulates bFGF expression promoter activ-
ity by regulating Egr-1 transcription. (A) Western blot (top) and semiquan-
titative RT-PCR (bottom) analyses of IGFBP-3’s effect on Egr-1 and Sp-1
protein and mRNA expression in H460 cells that had been infected with
Ad-BP-3 or Ad-EV for 2 days. (B) Luciferase assay to determine Egr-1’s effect
on bFGF expression. H460 cells transiently transfected with bFGF-Luc and
pEgr-1, pBP-3, or both; *P  .05, **P  .01. (C-D) RT-PCR analysis of
PDGFa and PDGFb mRNA expression in H460 cells (C) and Western blot
analysis of PDGF protein expression in H1299 and A549 cells (D) after
infection with Ad-EV or Ad-BP-3 or treatment with rBP-3. (E) Immunohisto-
chemical analysis of Egr-1, bFGF, and PDGF expression in H1299
xenografts 10 days after injection with Ad-EV or Ad-BP-3.
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active MAPK kinase (MEK; N3/S218E/S222D) (Figure 4B).36
pBP-3 and pBP-3-ggg reduced IGF-1– and 10% FBS-stimulated
Egr-1 promoter activity in both R (mouse embryonic fibroblasts
from an IGF-1R–null mouse) and R	 (R cells transfected with
IGF-1R) cells (Figure 4C).37 These findings suggest that the effects
of IGFBP-3 on Egr-1 promoter activity are IGF-1 independent.
We then determined whether this IGFBP-3–induced decrease in
Egr-1 expression affected IGFBP-3–mediated antiangiogenic activity.
To this end, we cocultured HUVECs with H460 cells cotransfected with
pEgr-1 and pBP-3 or pBP-3-ggg.As shown in Figure 4D, HUVECs that
had been cocultured with H460 cells transfected with Egr-1 and pBP-3
or pBP-3ggg had significantly reduced proliferation compared with
those cultured with H460 cells transfected with pBP-3 or pBP-3-ggg
alone, indicating attenuation of the antiangiogenic effects of pBP-3 and
pBP-3ggg by Egr-1 expression. Taken together, these results demon-
strate that IGFBP-3 has antiangiogenic activity in NSCLC cells by
inhibiting Egr-1 promoter activity through IGF-1–independent pathways.
IGFBP-3 inhibits Erk phosphorylation and subsequent Elk-1
activation, leading to a reduction in Elk-1 binding to SREs in
the Egr-1 promoter
The promoter region (935 to	12) of Egr-1 contains AP-1, Sp-1,
cAMP response element, and SREs and their adjacent Ets binding
sites.13 To identify the promoter elements that are involved in
IGFBP-3–regulated Egr-1 promoter activity, we assessed a 1.2-kb
Egr-1 promoter construct (A) and several 5-truncated deletion
mutant constructs (B to V)13 for promoter activity in H460 cells that
had been transiently cotransfected with pBP-3. Deletion of the
2 AP-1 binding sites and 3 Sp-1 binding sites (C construct) or the
CRE sites and two 3-SREs (SRE 1 and 2; D construct) had little
effect on promoter activity compared with the A construct, and the
promoter activities of these 3 constructs (A, C, and D) were
strongly inhibited by cotransfection with pBP-3 (Figure 5A). In
Figure 5. IGFBP-3 inhibits Egr-1 transcription by inactivating Erk-Elk1 and Elk1
binding to SRE sites in the Egr-1 promoter. (A-B) IGFBP-3’s effects on Egr-1
promoter activity. H460 cells were transiently cotransfected with Egr-1 Luc constructs
(A) or an Egr-1 Luc construct carrying mutations in the 3 5-SRE sites (SRE 3, 4, and
5; B), along with an empty vector (pEV) or pBP-3. The important genetic elements in
the Egr-1 regulatory region are shown, including the SRE sites, CRE sites, GC, and
TATA boxes. The data are the mean  SD from 3 independent experiments, with
4 replications per experiment. *P  .05, **P  .01, ***P  .001 compared with
pEV-transfected cells. (C) IGFBP-3 reduces in vivo binding of Elk-1 to the Egr-1
promoter. H460 cells, treated with rBP-3 or bovine serum albumin or infected with
Ad-BP-3 or Ad-EV, cross-linked and immunoprecipitated with antibodies specific for
IGFBP-3, Elk-1, SRF, or a normal serum control antibody (immunoglobulin). The
second primer denotes PCR samples using a pair of negative control primers correspond-
ing to the exon 1 sequence of the Egr-1 gene. (D-E) Western blot analysis for the indicated
proteins in H460 cells (D) and R and R	 cells (E) treated with the indicated
concentrations of rBP-3 for 2 days and stimulated with IGF-1 for 15 minutes.
Figure 4. IGFBP-3 inhibits Egr-1 expression independently IGF-1. (A-B) The
wild-type 1.2-kb Egr-1 promoter reporter construct (Egr1-A-Luc) was transiently
transfected, with or without pBP-3 or pBP-3-ggg, into NSCLC H460 cells. (A) Cells
were stimulated by cotransfection of plasmids containing mutants of K-Ras (V12) or
H-Ras (V12) or by exposure to hypoxia (1% O2) or -radiation (8 Gy). (B) Cells were
stimulated by IGF-1 (50 ng/mL) or FBS (10% and 30%) for 24 hours or cotransfected
with plasmids expressing CA MEK. (C) R (IGF-1R null mouse fibroblasts) and R	
(R cells transfected with IGF-1R) cell lines were cotransfected with Egr1-A-Luc and
pBP-3 or pIGFBP-3-ggg and then stimulated by IGF-1 (50 ng/mL) or FBS (10%) for
24 hours. The data are the mean  SD from 3 independent experiments, with
4 replicates per experiment. *P  .05, **P  .01. (D) In vitro evaluation of the
antiangiogenic potential of IGFBP-3. pBP-3–transfected H460 cells show less
stimulatory activity for HUVEC proliferation than untransfected H460 cells in a
coculture assay system. The values are the mean  SD from 2 separate experi-
ments, with 3 replicates per experiment. *P  .05, **P  .01, ***P  .001.
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contrast, removal of regions upstream of the SRE 1 or 2 sites (E and
F constructs) led to a dramatic reduction in Egr-1 promoter’s
activity and response to IGFBP-3 expression. Loss of all 5 SRE
sites and 2 CRE sites (B construct) led to a total elimination of
Egr-1 promoter activity. In contrast, pBP-3 had no effect on the
activity of the Egr-1 promoter that carried mutations in the
3 5-SRE sites (SRE 3, 4, and 5; CSREm345 construct; Figure 5B).
These findings suggest that the regions upstream of SRE 1 and
2, especially the 3 5-SRE sites (SRE 3, 4, and 5), contain promoter
elements that are regulated by IGFBP-3. The Egr-1 promoter
sequence that encompasses SRE sites 3-5 contains a cluster of Ets
motifs (GGA sequence),38 and these SRE sites and adjacent Ets
motifs are continuously occupied by ternary complex factors
transcription factors.39-41 The authors of previous studies have
shown that Elk-1, in combination with SRF, participates in the
initiation of Egr-1 transcription.42 Hence, we hypothesized that
IGFBP-3 treatment would inhibit the binding of Elk-1 or SRF to
the Egr-1 promoter, leading to reduced Egr-1 transcription. We
performed a ChIP assay by using 2 primer sets that encompassed
the 5-SRE sites or the first exon (as a negative control) and H460
cells treated with Ad-BP-3 or rBP-3. IGFBP-3 did not interact
directly with the SRE sites and did not affect SRF’s binding to these
sites (Figure 5C). In contrast, IGFBP-3 markedly reduced Elk-1’s
binding to the 5-SRE sites. The immunoprecipitates with preim-
mune serum (immunoglobulin) showed no significant binding to
these sites. These results suggest that IGFBP-3 regulates Egr-1
transcription by indirectly inhibiting Elk-1’s binding to the 5-SRE
sites in the Egr-1 promoter.
The authors of previous studies have indicated that transcrip-
tional Egr-1 activation is regulated by Elk-1 phosphorylation
through the MEK/Erk signaling cascade,20 which is required to
recruit SRF to the SREs in the Egr-1 promoter.43 Thus, we
determined whether IGFBP-3 interfered with the Raf-MAPK-Elk
phosphorylation cascade in H460 cells. A Western blot analysis
revealed that phosphorylated Erk1/2 (pErk1/2) and phosphorylated
Elk-1 (pElk-1) expression was dramatically reduced by IGFBP-3
treatment, whereas total and phosphorylated Raf and MEK1/2
levels were not affected (Figure 5D). Likewise, pBP-3 transfection
led to reduced pErk1/2 expression, with no change in pMEK1/2
levels (supplemental Figure 3). An additional experiment using R
and R	 cells treated with rBP-3 and stimulated with IGF-1 resulted
in reduced pErk1/2, pElk-1, and Egr-1 levels, with no change in
pMEK1/2 levels in both cell lines (Figure 5E). In contrast, neither
pIGF-1R nor pAkt levels were affected in rBP-3–treated R cells.
Together, these findings suggest that IGFBP-3 inhibits Erk1/2 and
Elk-1 activation through IGF-1–independent mechanisms, leading
to reduced binding of Elk-1 to SREs in the Egr-1 promoter and
Egr-1 transcription suppression.
IGFBP-3 binds to and inactivates Erk1/2
We determined the IGF-independent mechanisms by which
IGFBP-3 may deregulate Erk1/2 activation. IGFBP-3 has been
shown to act independently of the IGF system by binding to its own
receptors or other cellular proteins, although the mechanism by
which this occurs has not been clearly identified. Therefore, we
determined whether IGFBP-3 interacted with Erk1/2 using H1299
cells that do not express IGFBP-3.44 First, we performed coimmu-
noprecipitation assays by using H1299 cell lysates that had been
pretreated with rBP-3. H1299 cell immunoprecipitation with the
use of an anti-Erk1/2 antibody, followed by Western blotting for
IGFBP-3, revealed an association between Erk1/2 and rBP-3
(Figure 6A). Second, we determined in vitro whether IGFBP-3
directly interacts with Erk1/2. rBP-3 protein conjugated to NTA-
agarose beads was incubated with H1299 cell lysates, washed,
electrophoresed, and immunoblotted for Erk1/2 and p38. We found
an interaction between IGFBP-3 and Erk1/2 that increased with the
amount of the cell lysate added (Figure 6B). However, we did not
detect an interaction between p38
 and IGFBP-3.
Because large amounts of recombinant protein may cause coimmu-
noprecipitation artifacts and binding of cellular extracts to IGFBP-3
conjugated to affinity beads may not establish that IGFBP-3 interacts
with Erk1/2 in vivo, we performed coimmunoprecipitation assays by
using H1299 cell lysates that had been transfected with expression
vectors carrying IGFBP-3 (pBP-3; Figure 6C) or Flag-tagged
Figure 6. IGFBP-3 binds to and inactivates Erk. (A,C-D) H1299 cells were
pretreated with rBP-3 for 3 hours (A) or transiently transfected with pEV or pBP-3 (C),
or with pEV-Flag or pBP-3-Flag (D) for 2 days. Lysates from H1299 cells were used
for immunoprecipitation with rabbit anti-Erk1/2 antibody. Erk1/2, Flag, IGFBP-3, and
p38
 were detected by Western blotting. Whole cell lysates (WCLs) were subjected
to a Western blot assay for phospho-Erk and phospho-p38 to determine specific
inhibition of Erk by IGFBP-3. EV: empty vector. pBP-3-Flag: pCMV6-IGFBP-3-Flag.
(B) Ni-NTA bead-bound his-tagged rBP-3 was incubated with H1299 whole cell lysate
(150, 300, or 450 g) for 5 hours before being washed and subjected to Western blot
analysis for Erk1/2, p38
, and IGFBP-3. (E) H1299 cells were incubated with rBP-3
for 3 hours and stimulated with 10% FBS; samples were removed at different time
points, as shown. The cell lysates were used for immunoprecipitation with rabbit
anti-Erk antibody. Western blotting was used to detect IGFBP-3 and Erk from
immunoprecipitation or whole cell lysates.
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IGFBP-3 (pBP-3-Flag; Figure 6D). We found an association
between Erk1/2 and IGFBP-3 in these cells, further confirming an
Erk1/2-IGFBP-3 interaction. In contrast, a control immunoprecipi-
tation using an anti-p38
 antibody revealed that p38
 was not
associated with IGFBP-3 (Figure 6D bottom). IGFBP-3-Flag
expression induced a marked decrease in Erk phosphorylation, with
a slight increase in p38
 phosphorylation. These findings suggest a
direct and specific interaction between Erk1/2 and IGFBP-3. Thus,
the interaction between IGFBP-3 and Erk does not appear to be an
artifact of the high IGFBP-3 concentration.
We then correlated Erk1/2 activation with the association
between IGFBP-3 and Erk1/2 by incubating H1299 cells with
rBP-3 in serum-free conditions and analyzing samples obtained at
several time points up to 30 minutes after stimulation with 10%
FBS. IGFBP-3 was strongly associated with Erk1/2 under the
serum-starved condition (Figure 6E). We found that 10% FBS
stimulated Erk1/2 activation in control cells; however, Erk1/2
remained inactive in rBP-3–treated cells in which IGFBP-3
associated with Erk1/2. IGFBP-3 levels in H1299 cells gradu-
ally decreased 15 minutes after FBS stimulation, and Erk1/2
was rephosphorylated. These findings suggest that IGFBP-3
binds to Erk1/2, obstructing its activation and downstream
signaling cascades.
Transcolocalization of IGFBP-3 with Erk in H1299 cells
We performed confocal microscopy to determine whether
exogenously supplied recombinant IGFBP-3 protein entered the
cytosol and interacted with Erk. Serum-starved H1299 cells
were treated with rBP-3 (10 g/mL) for 1 hour; the cells were
collected after 0, 10, 30, and 60 minutes and subjected to
immunofluorescence staining with antibodies against IGFBP-3
or Erk1/2. As shown in Figure 7A, IGFBP-3 was localized near
the membrane and in the cytosol 10 minutes after treatment and
translocalized more to the cytosol by 60 minutes. Furthermore,
IGFBP-3 and Erk1/2 colocalization at the cytoplasmic and
perinuclear regions was markedly increased after 60 minutes.
Interestingly, nuclear colocalization of IGFBP-3 and Erk1/2 was
not detected, suggesting that IGFBP-3 binds and inactivates
Erk1/2, resulting in suppression of Erk1/2 nuclear localization.
Discussion
IGFBP-3 is known to have IGF-independent antiangiogenic antitu-
mor activities; however, mechanisms by which the IGF-indepen-
dent activities of IGFBP-3 are mediated are not clearly understood.
In this article, we have demonstrated a novel principal mechanism
by which IGFBP-3 blocks tumor angiogenesis induced by NSCLC
cells, including blocking the autocrine and paracrine loops of
angiogenic factors by inhibiting the production of angiogenic
factors such as bFGF and PDGF. IGFBP-3 appears to bind to and
inactivate Erk1/2, which results in Elk-1 inactivation and Elk-1–
SRE binding suppression in the Egr-1 promoter. Ultimately, this
inhibits the transcription of Egr-1 and its target genes, including
bFGF and PDGF.
Figure 7. Translocalization and colocalization of rBP-3 with Erk in H1299 cells. (A) H1299 cells on cover slips were treated with rhIGFBP-3 (10 g/mL) and fixed at 0, 10,
30, and 60 minutes after being washed 3 times in PBS. Nuclei (blue) were stained with Hoechst 33342 (1 g/mL). Erk1/2 (green) was stained with mouse anti-Erk antibody and
secondary antibodies conjugated with Alexa Fluor 488. IGFBP-3 (red) was stained with rabbit anti-IGFBP-3 antibody and secondary antibodies conjugated with Alexa Fluor
568. For the negative control, cells treated with rhIGFBP-3 for 60 minutes were stained with secondary but not primary antibodies. Neg Con: negative control. Colocalization
map: schematic plot of colocalization; white dots represent the colocalization of Erk and IGFBP-3. The empty arrowhead indicates IGFBP-3 accumulation near the cell
membrane. (B) Schematic model of IGFBP-3’s angiogenesis inhibition. IGFBP-3 inhibits tumor angiogenesis by IGF-dependent and -independent mechanisms. In the
IGF-independent mechanism, IGFBP-3 directly binds to and inactivates Erk1/2, prevents Elk-1 activation and binding between activated Elk-1 and Egr-1 promoter, and inhibits
expression of Egr-1 and its target genes, including bFGF and PDGF, resulting in suppression of angiogenesis and tumor growth.
2628 KIM et al BLOOD, 1 SEPTEMBER 2011  VOLUME 118, NUMBER 9
Because IGFBP-3 has been shown to inhibit vascular endothe-
lial cell survival45,46 and induce tumor vasculature normalization,47
it is believed to have antiangiogenic properties. In support of this
notion, IGFBP-3–mediated antitumor activities have been found to
involve angiogenesis suppression in various cancer types.7,8,45
However, to date, the mechanisms by which IGFBP-3 regulates
angiogenesis are not understood.
We investigated the mechanisms that mediate IGFBP-3’s antian-
giogenic activity and found that it regulates the expression of bFGF
and PDGF, potent angiogenic factors, in NSCLC, HNSCC, and
vascular endothelial cells. Because the Egr-1 transcription factor
plays a role in regulating these angiogenic factors’ expression by
binding to the G/C-rich consensus element in their promoters, we
determined effects of IGFBP-3 on Egr-1 expression. As expected,
IGFBP-3 decreased Egr-1 promoter activity and expression; it also
led to reduced transcription of Egr-1 target genes, including bFGF
and PDGF. Furthermore, Egr-1 overexpression restored the bFGF
promoter and angiogenic activities that had been suppressed by
IGFBP-3. Therefore, IGFBP-3 may regulate tumor angiogenesis
through mechanisms that involve Egr-1, a transcription factor for
bFGF and PDGF expression.
IGFBP-3 leads to decreased clusterin expression, which is induced
by stress-induced Egr-1 transactivation through IGF-1R-Src-MEK-Erk
signal transduction cascade activation.48 Hence, the inhibitory effect of
IGFBP-3 on Egr-1 expression and the resultant reduction in bFGF and
PDGF transcription may have occurred through IGF-dependent mecha-
nisms. However, Egr-1 regulation by IGFBP-3 appears to include novel
IGF-independent mechanisms for the following reasons: (1) both
wild-type IGFBP-3 and the non-IGF–binding IGFBP-3-ggg mutant
suppressed the Egr-1 promoter activity that had been stimulated by
mitogenic and nonmitogenic stimuli in H1299, IGF-1R–null (R), and
IGF-1R–positive (R	) cells; and (2) Egr-1 overexpression abrogated the
antiangiogenic activity of wild-type IGFBP-3 and the IGFBP-3-ggg
mutant in NSCLC cells. Our gross promoter deletion and mutation
analyses revealed that the SREs and their adjacent Ets sites are critical to
the IGFBP-3–mediated reduction in Egr-1 transcription. Importantly,
our ChIP assay results showed that Elk-1’s binding to SRE sites 3-5 was
inhibited by IGFBP-3 treatment, whereas SRF binding was not affected.
This pattern of constitutive binding by SRF without ternary complex
formation is consistent with some49,50 SRE-mediated transcription
models. One possible mechanism of the IGFBP-3–mediated down-
regulation of Elk-1 binding is inactivation of the Ras-Raf-MEK1/2-
Erk1/2 signaling cascade, which phosphorylates and activates Elk-1 and
regulates SRE-Ets–mediated Egr-1 transcription.49 The Ras-Raf-MEK1/
2-Erk1/2 pathway regulates endothelial cell behavior during angio-
genesis by stimulating cell proliferation, survival, migration, and
invasion.51,52 MEK1 knockout mice have defects in angiogenesis in
the placenta, resulting in embryonic lethality.53 Surprisingly, our
biochemical analysis revealed that rBP-3 treatment resulted in Erk1/2
inactivation and suppression of Elk-1 and Egr-1 expression without
concordant inactivation of MEK1/2 in NSCLC, R	, and R cells. These
findings demonstrate that IGFBP-3 can inactivate Erk/Elk-1 indepen-
dent of MEK-1.
Scaffolding proteins, such as Ras kinase suppressor, MAPK
organizer-1, and MEK partner-1, are known as regulators of the
Ras-Raf-MEK signaling pathway.54 This knowledge led us to begin
investigating the potential involvement of these scaffolding pro-
teins in IGFBP-3–mediated Erk1/2 inactivation. However, we
detected no interactions among these scaffolding proteins and
IGFBP-3 in H1299 or H460 cells that had been transfected with
pBP-3 or infected with Ad-BP-3 (data not shown). Furthermore,
interaction between these scaffolding proteins and signaling com-
ponents of Ras-Raf-MEK-Erk signaling was not appreciably
changed by the IGFBP-3 expression. These findings suggest that
IGFBP-3 inactivates Erk1/2 through mechanisms that are indepen-
dent of these scaffolding proteins. Surprisingly, our data clearly
demonstrated that IGFBP-3 can directly interact with Erk1/2,
leading to Erk1/2 activity suppression. This interaction appeared
to be Erk1/2-specific because the high level of IGFBP-3
obtained after treatment with recombinant protein or transient
transfection with mammalian expression vector did not induce
p38 binding.
In summary, our data provide a model of an IGF-independent
mechanism through which IGFBP-3 inhibits the Erk1/2-Elk-1
activation loop and thus reduces Egr-1 expression. The intracellular
translocalization of IGFBP-3 may have been mediated by mem-
brane receptors, as proposed in previous studies.55-57 In this study,
recombinant IGFBP-3 translocated through the membranes into the
cytoplasm. Additional mechanisms underlying the IGFBP-3–
mediated inactivation of Erk1/2 should be explored (such as
whether IGFBP-3’s binding to surface receptors triggers phospha-
tases to dephosphorylate Erk1/2), our current data provide a
schematic model in which IGFBP-3 directly binds to Erk1/2 and
inhibits its activation, thereby preventing Elk-1 phosphorylation.
IGFBP-3’s dissociation from Erk1/2 during mitogen stimulation
allows Erk1/2 activation, leading to Elk-1–induced expression of
Egr-1, a master transcription factor that regulates genes that are
strongly implicated in tumor growth and angiogenesis. Ultimately,
this activation stimulates the Egr-1–mediated transcriptional events
observed in cancer cells (Figure 7B).
Antiangiogenic therapies currently in clinical trials induce
acquired resistance in cells by causing them to shift to other growth
factor-induced angiogenesis mechanisms. Therefore, IGFBP-3’s
ability to regulate multiple potent angiogenic factors makes it an
attractive antiangiogenic, antineoplastic agent. However, because
reduced tumor vascularization after antiangiogenic therapy could
induce hypoxia and thus promote the spread of cancer cells toward
a more oxygenated environment,58 extensive studies are needed
before clinical trials in which IGFBP-3 overexpression is induced
are considered. In this work, we did not determine the exact
mechanisms by which IGFBP-3 enters cells and by which serum
stimulation induces IGFBP-3 dissociation from Erk1/2, although
serum stimulation may activate proteases, including various MMPs,
that cause IGFBP-3’s degradation.59-61 Further studies are war-
ranted to understand the molecular mechanisms of IGFBP-3-
Erk1/2 interaction.
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